Congressmen Brett Guthrie and Morgan Griffith have announced a second hearing in their series focused on reducing health care costs for Americans. The hearing, titled “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain,” is scheduled for February 11, 2026, at the Rayburn House Office Building. Guthrie and Griffith emphasize their commitment to addressing the root causes of high prescription drug costs by involving various stakeholders from the pharmaceutical industry.
“This marks the second hearing in our health care affordability series, confirming Republicans’ commitment to meaningfully lowering the cost of care for American families,” said Chairmen Guthrie and Griffith. They aim to explore solutions that ensure prescription drugs remain accessible and affordable.
James Gelfand, President and CEO of The Erisa Industry Committee (ERIC), will testify at the hearing. ERIC represents large employers who provide health coverage to millions of Americans. Gelfand’s testimony highlights how vertical integration within the drug supply chain contributes to rising costs through practices like exclusionary rebates and steering patients toward higher-cost drugs.
The ERISA Industry Committee supports increased transparency and oversight across all actors in the drug supply chain, including pharmacy benefit managers (PBMs), wholesalers, group purchasing organizations (GPOs), third-party administrators, brokers, and consultants. Gelfand advocates for reforms that would enhance transparency, reduce anti-competitive behavior, accelerate access to biosimilars, and enforce fairness in provider contracting.
The public can attend or view a livestream of the hearing on energycommerce.house.gov. Questions regarding the event can be directed to Annabelle Huffman or Katie West via email.
